
Manufacturers of Dupixent Facing Lawsuits Over Drug Outcomes
Multiple Lawsuits Moving Forward After Plaintiffs Claim that Dupixent May Cause Cutaneous T-Cell Lymphoma MANHATTAN, NEW YORK (June 12, 2026) – Sanofi and Regeneron are facing a variety of lawsuits over claims that Dupixent may cause or potentially accelerate Cutaneous T-Cell Lymphoma. Plaintiffs were using Dupixent to treat their eczema













